One of the barriers to the development of effective adoptive cell transfer therapies (ACT), specifically for genetically engineered T-cell receptors (TCRs), and chimeric antigen receptor (CAR) T-cells, is target antigen heterogeneity. It is thought that intratumor heterogeneity is one of the leading determinants of therapeutic resistance and treatment failure. While understanding antigen heterogeneity is important for effective therapeutics, a good therapy strategy could enhance the therapy efficiency. In this work we introduce an agent-based model to rationalize the outcomes of two types of ACT therapies over heterogeneous tumors: antigen specific ACT therapy and multi-antigen recognition ACT therapy. We found that one dose of antigen specific ACT therapy should be expected to reduce the tumor size as well as its growth rate, however it may not be enough to completely eliminate it. A second dose also reduced the tumor size as well as the tumor growth rate, but, due to the intratumor heterogeneity, it turned out to be less effective than the previous dose. Moreover, an interesting emergent phenomenon results from the simulations, namely the formation of a shield-like structure of cells with low oncoprotein expression. This shield turns out to protect cells with high oncoprotein expression. On the other hand, our studies suggest that the earlier the multi-antigen recognition ACT therapy is applied, the more efficient it turns. In fact, it could completely eliminate the tumor. Based on our results, it is clear that a proper therapeutic strategy could enhance the therapies outcomes. In that direction, our computational approach provides a framework to model treatment combinations in different scenarios and explore the characteristics of successful and unsuccessful treatments.
提出了一个基于非广延熵的肿瘤生长模型。演化方程依赖于非广延参数q。指数增长律、逻辑增长律和Gompertz增长律都是广义模型的特例。不同肿瘤的实验数据已被证明符合所有这些肿瘤生长规律。最近报道的研究表明,肿瘤的存在遵循幂律行为。我们的模型也能够拟合q<1的这些数据。我们表明,对于q<1,常用的恒定强度治疗无法将肿瘤大小减小到零。与Gompertzian肿瘤的情况一样,对于- q<1,需要晚期致密化方案。然而,这些q<1的肿瘤甚至比Gompertzian肿瘤更难治愈。虽然对于Gompertzian肿瘤,线性增加的细胞杀伤函数足以在指数衰减后将肿瘤大小减小到零,但在q<1的肿瘤的情况下,仅用指数增加的细胞杀伤函数获得指数衰减。这意味着这些肿瘤需要更积极的治疗方案。我们已经证明,对于Gompertzian肿瘤,对数晚期强化足以使肿瘤大小渐近减小到零。这不是最快的方法,但对患者来说更容易接受。然而,对于q 1的肿瘤<1 we would need at least a linearly increasing therapy in order to achieve a similarly effective reduction. When q>,使用传统的恒定强度治疗可以将肿瘤大小减小到零。
Renormalization of radiobiological response functions by energy loss fluctuations and complexities in chromosome aberration induction: deactivation theory for proton therapy from cells to tumor control
First image-guided treatment of a mouse tumor with radioactive ion beams
GSI Helmholtzzentrum für Schwerionenforschung(GSI亥姆霍兹重离子研究中心);Ludwig-Maximilians-Universität München (LMU)(慕尼黑路德维希-马克西米利安大学);Technische Universität Darmstadt(达姆施塔特工业大学);Technische Hochschule Mittelhessen(黑森应用技术大学);Justus-Liebig-Universität Gießen(吉森约翰内斯·谷登堡大学);Helmholtz Research Academy Hesse for FAIR (HFHF)(黑森FAIR亥姆霍兹研究院);University Federico II(那不勒斯费德里科二世大学)